Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Extracellular vesicles (EVs) act as molecular mediators in the tumor microenvironment, by shuttling information contained within malignant cells and functioning as regulators of the immune system. Circular (circ)RNAs are characterized by a closed loop-like structure that makes them more stable in the extracellular milieu and suitable to be packaged inside EVs. circPVT1 (hsa_circ_0001821) showed an oncogenic role in several cancer types and immunosuppressive properties in myeloid and lymphoid cell subsets. In this study, we characterized EVs from acute myeloid leukemia (AML) patients in terms of size, concentrations, surface markers and circPVT1 cargo. We showed that circPVT1 is overexpressed by primary blast cells from newly-diagnosed AML patients compared with hematopoietic stem-progenitor cells and is released as cell-free RNA in the plasma. We isolated EVs from the plasma of AML patients and healthy subjects by size exclusion chromatography and characterized them by nanoparticle tracking analysis. EVs from patients' plasma are larger compared with those from healthy subjects and their surface profile is characterized by higher levels of the leukemic cell markers CD133, CD105, CD49e and other immune-related epitopes, with differences according to AML molecular profile. Moreover, digital PCR analysis revealed that circPVT1 is more abundant inside EVs from the plasma of AML patients compared with healthy subjects. Our findings provide new insights on the features and content of AML EVs and suggest a role of circPVT1 in the crosstalk between AML cells and the tumor microenvironment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:165 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 165(2023) vom: 01. Sept., Seite 115235 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghetti, Martina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Completed 17.08.2023 Date Revised 17.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2023.115235 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360357563 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360357563 | ||
| 003 | DE-627 | ||
| 005 | 20231226082838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2023.115235 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360357563 | ||
| 035 | |a (NLM)37536029 | ||
| 035 | |a (PII)S0753-3322(23)01026-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghetti, Martina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2023 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Extracellular vesicles (EVs) act as molecular mediators in the tumor microenvironment, by shuttling information contained within malignant cells and functioning as regulators of the immune system. Circular (circ)RNAs are characterized by a closed loop-like structure that makes them more stable in the extracellular milieu and suitable to be packaged inside EVs. circPVT1 (hsa_circ_0001821) showed an oncogenic role in several cancer types and immunosuppressive properties in myeloid and lymphoid cell subsets. In this study, we characterized EVs from acute myeloid leukemia (AML) patients in terms of size, concentrations, surface markers and circPVT1 cargo. We showed that circPVT1 is overexpressed by primary blast cells from newly-diagnosed AML patients compared with hematopoietic stem-progenitor cells and is released as cell-free RNA in the plasma. We isolated EVs from the plasma of AML patients and healthy subjects by size exclusion chromatography and characterized them by nanoparticle tracking analysis. EVs from patients' plasma are larger compared with those from healthy subjects and their surface profile is characterized by higher levels of the leukemic cell markers CD133, CD105, CD49e and other immune-related epitopes, with differences according to AML molecular profile. Moreover, digital PCR analysis revealed that circPVT1 is more abundant inside EVs from the plasma of AML patients compared with healthy subjects. Our findings provide new insights on the features and content of AML EVs and suggest a role of circPVT1 in the crosstalk between AML cells and the tumor microenvironment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a CirRNA | |
| 650 | 4 | |a CircPVT1 | |
| 650 | 4 | |a Extracellular vesicles | |
| 650 | 4 | |a Immune system | |
| 650 | 7 | |a RNA, Circular |2 NLM | |
| 700 | 1 | |a Vannini, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Bochicchio, Maria Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Azzali, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Ledda, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Marconi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Melloni, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Rondoni, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Chicchi, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Angeli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Ghelli Luserna di Rorà, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Giannini, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Zacheo, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Biguzzi, Rino |e verfasserin |4 aut | |
| 700 | 1 | |a Lanza, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Martinelli, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Simonetti, Giorgia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 165(2023) vom: 01. Sept., Seite 115235 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:165 |g year:2023 |g day:01 |g month:09 |g pages:115235 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2023.115235 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 165 |j 2023 |b 01 |c 09 |h 115235 | ||